MarketCap
Facebook
X
Telegram
Cronos Group Revenue | CRON
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cronos Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 147 M | 118 M | 87.2 M | 86.7 M | - | 46.7 M | 23.8 M | 11.5 M | 3.25 M | 412 K | - | - | -196 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 147 M | -196 K | 52.4 M |
Quarterly Revenue Cronos Group
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53 M | 45.2 M | 36.3 M | 33.5 M | 32.3 M | 34.3 M | 27.8 M | 25.3 M | 24.8 M | 19 M | 20.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53 M | 19 M | 32 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.78 | 2.41 % | $ 3.35 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 6.61 | 3.4 % | $ 98.2 M |  USA |
 |
Emergent BioSolutions
EBS
|
743 M | $ 6.42 | 3.05 % | $ 343 M | USA |
 |
Evolus
EOLS
|
297 M | $ 8.04 | 2.55 % | $ 518 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 34.0 | 0.09 % | $ 1.25 B | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 1.48 | 1.01 % | $ 188 M | USA |
 |
Pacira BioSciences
PCRX
|
726 M | $ 25.1 | 0.02 % | $ 1.12 B | USA |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 13.83 | 1.24 % | $ 1.92 B | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.47 | 0.11 % | $ 176 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 7.94 | 0.75 % | $ 286 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 4.63 | 2.69 % | $ 231 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 8.96 | 2.98 % | $ 784 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.37 | 1.87 % | $ 354 M |  Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 1.29 | 2.29 % | $ 2.17 M | USA |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.16 | 0.23 % | $ 25 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.37 | 0.4 % | $ 34.7 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 16.7 | 1.18 % | $ 19.2 B | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 5.93 | 1.11 % | $ 2.2 B | Canada |
 |
cbdMD
YCBD
|
19.2 M | $ 0.48 | 0.94 % | $ 1.93 M | USA |
 |
Tilray
TLRY
|
821 M | $ 4.12 | 2.59 % | $ 3.67 B | Canada |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 0.95 | 1.97 % | $ 283 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.07 | 2.05 % | $ 102 M | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.83 | 2.41 % | $ 210 M | Canada |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | - | - | $ 150 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |